In collaboration with Riga Technical University, the CERN Accelerator School is proud to present a CAS course on Medical Accelerators.

Particle accelerators, known since decades as cornerstones of fundamental physics research, nowadays evolved into indispensable tools for society across diverse fields. This course focuses on profound and widespread accelerator applications in medicine, particularly in oncology and in nuclear medicine. By bridging the communities of accelerator science and medical physics, we will provide a comprehensive overview of the field from both technological and clinical perspectives.

For more information and registration, please visit the dedicated webpage of the course.

PRISMAP has just returned from the annual congress of the European Association of Nuclear Medicine (EANM – Barcelona, 6–8 October 2025). With 9,431 congress participants (including online participants) and 2,991 abstracts submitted, this year's congress set a new record. On the occasion of the 40th anniversary of the EANM Congress, PRISMAP and its representatives were more present than ever, underlining the growing importance of PRISMAP.

The highlight of PRISMAP's contributions to the congress was a dedicated session on Sunday, 5 October 2025. As part of a thematic block on EU projects, PRISMAP was able to share its results and perspectives. To familiarise the audience with PRISMAP, Thierry Stora from CERN first presented the structure and scope of PRISMAP, the number of projects funded and the development prospects. Eleni Gourni, Bern, Switzerland, reported on her experiences as a PRISMAP user with Sc-47 from PRISMAP. She described the process from applying for a PRISMAP user project to its successful implementation. Finally, Clemens Decristoforo from Innsbruck, Austria, explained how PRISMAP was involved in networking activities with a focus on harmonisation and standardisation. The session ended with a lively discussion among interested users about logistics and supply chains, the application process and other questions about the scope and future of the project, underscoring the great inte

rest and need for novel radionuclides for medical applications.

PRISMAP plays an important role in current political decision-making processes at European Commission level, as was also made clear at the EANM Congress. According to Paola Erba, President of EANM, and Wim Oyen (former President and Board Member of EANM), PRISMAP acts as an EU platform for research in the field of biomedical radionuclides and is in contact with various institutions, in particular the European Medicines Agency.

In addition, PRISMAP was represented by a number of speakers, poster presenters and chairs from the consortium, as well as by users who presented their projects made possible by PRISMAP's services. We are particularly pleased that three of our presentations were classified as ‘top rated oral presentations’ by the EANM:

• N. Kumar, E. Gourni et al: Targeted Radionuclide Therapy of Prostate Cancer using a177 Lu- and47 Sc-labeled Gastrin-Releasing Peptide Receptor Antagonist. Evaluation as Monotherapy and in Combination with Everolimus
• A. Gustafsson, M. Nestor et al: Tb, or Not Tb - Exploring Terbium-161 for CD44v6Targeted Radionuclide Therapy
• M. Salek, J. W. Engle et al: Small cyclotron production of n.c.a.103 Pd from Rh targets for targeted radionuclide therapy

PRISMAP will soon come to an end, with a closing date of 31 December 2025.

On Tuesday, 14 October 2025 from 16.30 to 17.15 CEST, PRISMAP coordinator Thierry Stora will present our view of PRISMAP's achievements and future prospects in a follow-up project in a 45-minute webinar, including a short presentation followed by an open discussion.

For more information and the meeting link please refer to our dedicated event page. 

Below is an overview of PRISMAP members’ participation at the 2025 EANM conference, including poster sessions, presentations, and details of the special PRISMAP Session on Sunday, 5 October.

Join our special session: a unique opportunity to learn about PRISMAP’s journey, user experiences, and translational applications of its radionuclides in nuclear medicine research and therapy.

5 October 8:32—8:36 Poster presentation

Dr. Naveen Kumar — Preclinical Evaluation of a 47Sc-labeled Gastrin Releasing Peptide-based Radioantagonist for the Targeted Management of Breast Cancer

5 October 9:16—9:20 Poster presentation

Melissa Crabbé — The absorbed dose-response relationship of the Auger electrons from La-135

7 October 8:30—8:40 Poster presentation

Dr. Naveen Kumar — Targeted Radionuclide Therapy of Prostate Cancer using a 177Lu- and 47Sc-labeled Gastrin-Releasing Peptide Receptor Antagonist. Evaluation as Monotherapy and in Combination with Everolimus

Poster presentation

Kristof Baete — Nuclear medicine equipment standardisation for clinical translation: a case study with Tb-161

Poster presentation

D. Pawlak and R. Mikołajczak — Small-scall production of 161Tb

PRISMAP will soon come to an end, with a closing date of 31 December 2025.

This opens the door towards the next step: We have just submitted a proposal for a successor project PRISMAP+, which we hope the EC will select for funding so that we can start it in late Spring 2026.

Our help desk will remain open during the transition phase, and interested users are invited to contact us through this channel. 

A first call for user projects under PRISMAP+ would be opened towards the end of 2026.

On Tuesday, 14 October 2025, PRISMAP coordinator Thierry Stora will present our view of PRISMAP's achievements and future prospects in a follow-up project in a 45-minute webinar, including a short presentation followed by an open discussion.

To get the full picture and celebrate with us, join us at the PRISMAP closing conference, which will take place in Warsaw and online on 18 and 19 November 2025. There, we will present the final results of PRISMAP and our plans for the future in detail.

To keep informed, make sure you are registered as part of the PRISMAP community. 

The PRISMAP Final Event will take place in Warsaw this coming fall. More information and details will be available on its dedicated page. In the meantime, save the date — 19 November — and stay tuned for further updates!

Our workshop on emerging infrastructures was immediately followed by our 8th consortium meeting: another 2.5 days were dedicated to the lessons learnt from the project so far and the plans for the final project phase and beyond. In addition, we had the pleasure of meeting Belgian companies active in the field of medical radionuclides during a ‘PRISMAP meets industries’ session. Our public event, which has already become a tradition at our consortium meetings, rounded off the meeting with our project news and exciting reports from our user projects. Many, many thanks to SCK-CEN, our host in this beautiful lake district near Mol/Belgium!

We have just returned from the second PRISMAP workshop on emerging infrastructures - two intensive days of presentations, poster exhibition and discussions, as well as a half-day visit to the SCK CEN infrastructures MYRRHA, BR2 and CRF. 

The programme included sessions on the assessment of emerging infrastructures for specific radionuclides, isotope separation for isotope enrichment and technical developments for radionuclide production. A round table discussion on innovative radionuclides and user needs rounded off the workshop. 

Stay tuned, a white paper will be produced based on this workshop

Researchers at our partner organisation SCK CEN have recently achieved a new milestone in the development of ISOL@MYRRHA: the first production and mass separation of an ion beam. The team successfully separated the stable isotopes of rubidium using a newly developed ISOL system installed for off-line operation at SCK CEN. More information you can find on the SCK CEN website. 

A PRISMAP session will take place at the Workshop on radionuclide production and medical application (Oslo, 12-16 May 2025), organised by the new Norwegian Nuclear Research Centre at University of Oslo and including a discussion on the preparation of the PRISMAP+ successor project and a Scandinavian node.

You are all very welcome to join and submit an abstract, preferentially by 1 Mar 2025. 

Some grants may be made available to young researchers for travel costs.

Stay tuned, more information and registration will be made available soon. 

You are all cordially invited to the public event, which is being organised in parallel with the upcoming PRISMAP school "Current and Innovative Radionuclides for Medical Imaging and Therapy" in Riga. 

The event aims to highlight advancements in the multidisciplinary field of nuclear medicine, including radiopharmaceutical sciences, radioisotope production, clinical applications, and technological solutions.It is designed for medical doctors, residents, trainees, young researchers, and students at the Bachelor, Master, or PhD level in nuclear medicine, physics, or chemistry, as well as anyone with an interest in the field.

For more details regarding the programme and registration, please refer to the dedicated page on the PRISMAP website. 

The ISOLPHARM group of PRISMAP partner INFN will arrange a thematic workshop entitled 'ISOL technique for the production of medical radionuclides' at the FisMat 2025 conference, which will take place in Venice on 7-11 Jul 2025.

For registration and abstract submission please refer to the workshop webpage. More information about FisMat 2025 you can find on the conference website. 

Submission deadline is 31 Mar 2025. 

Join us for our next PRISMAP school on "Current and Innovative Radionuclides for Medical Imaging and Therapy", taking place on 19-21 Feb 2025 in Riga, Latvia!

The school brings together medical doctors, radiology and nuclear medicine trainees, young researchers and Master and PhD students in nuclear medicine, physics and chemistry from Baltics and Europe with the aim to introduce the latest trends in radiopharmaceutical sciences, including radiolabelled chemistry, synthesis and dosimetry. The event includes theoretical lectures, scientific sessions and a public event.

The course will also include a visit to the Cyclotron facility in Riga and a social programme. Overall, trainees will acquire scientific knowledge to understand the most important aspects in radiochemistry, nuclear medicine, theranostics especially in precision medicine context.

Green light for IMPACT: The upgrade at the proton accelerator facility at the Paul Scherrer Institute PSI planned for the coming years will be implemented. Funding for this two-part enhancement was assured within the framework of the ERI Dispatch 2025-2028. 

More information is available on the PSI website. 

The National Laboratories of Legnaro, part of the Italian National Institute for Nuclear Physics (LNL-INFN) informed today that its SPES facility produced its first radioactive ion beam on 14 Nov 2024. More information is available on their website.